Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS
In both RMS and PPMS, early treatment with ocrelizumab helps to prevent additional cerebellar volume loss compared with delayed switching to ocrelizumab. Further analysis is needed to fully understand the clinical impact of cerebellar atrophy.
Authors
- Corrado Bernasconi (ORCID: https://orcid.org/0000-0002-1019-5468)
- Shannon Kolind (ORCID: https://orcid.org/0000-0003-1362-1968)
- Björn Tackenberg
- Katrin Parmar (ORCID: https://orcid.org/0000-0002-4251-6238)
- Stefano Magon (ORCID: https://orcid.org/0000-0003-1517-7581)
- Anthony Traboulsee (ORCID: https://orcid.org/0000-0002-0351-9639)
- Irene M. Vavasour (ORCID: https://orcid.org/0000-0001-9286-0953)
- Till Sprenger (ORCID: https://orcid.org/0000-0002-5390-819X)
- Laura Gaetano (ORCID: https://orcid.org/0000-0002-5214-2858)
- Matilde Inglese (ORCID: https://orcid.org/0000-0002-9610-0297)
- Ludwig Kappos
- Douglas Lorne Arnold (ORCID: https://orcid.org/0000-0003-4266-0106)
- Jerry S. Wolinsky (ORCID: https://orcid.org/0000-0002-8197-2762)
- Amit Bar‐Or (ORCID: https://orcid.org/0000-0001-7179-0335)
- Ulrike Bonati (ORCID: https://orcid.org/0000-0003-1717-6419)
- Haz-Edine Assemlal
Institutions
- Roche (Switzerland) (CH)
- Montreal Neurological Institute and Hospital (CA)
- University of British Columbia (CA)
- University of Basel (CH)
- University Hospital of Basel (CH)
- NeuroRx Research (Canada) (CA)
- Reha Rheinfelden (CH)
- McGill University (CA)
- University of Pennsylvania (US)
- University of Genoa (IT)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1177/13524585251325086
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- F. Hoffmann-La Roche